X
skip to main content
Logo

The Terry Fox Research Institute (TFRI), named for Canadian icon Terry Fox, is built on Terry's dream to end cancer through research.

News & Notices

  • 2017 New Investigator award recipients announced

    Awards to three New Investigators were made by TFRI in late December 2016, for a total investment of $1.3 million. Each award is valued at $450,000 for a term of three years, commencing Jan. 1, 2017. Recipients are: Dr. Hanson He (UHN), Dr. Frédérick Mallette (UdeM), and Dr. Peter Stirling (BC Cancer Agency).

    Read More View all notices

  • Whole genome sequencing study helps BC team learn how aggressive follicular lymphoma occurs in patients

    Follicular lymphoma (FL), the second most common form of non-Hodgkin lymphoma, is a largely incurable disease of B cells, yet in many cases, because of its indolent nature, survival can extend to well beyond 10 years following diagnosis. Yet in a small number of cases, histological transformation - where fast-growing cells outnumber the smaller, slow-growing cells - or early progression to aggressive lymphoma occurs.

    Read More View all notices

  • Stem cell-based test predicts leukemia patients' response to therapy to help tailor treatment

    TORONTO, Canada – Dec. 7, 2016 – Leukemia researchers at Princess Margaret Cancer Centre, with funding from Terry Fox and others, have developed a 17-gene signature derived from leukemia stem cells that can predict at diagnosis if patients with acute myeloid leukemia (AML) will respond to standard treatment.

    Read More View all notices

  • Ontario Node Symposium in Toronto draws large crowd; images posted

    TFRI's Ontario Node Research Symposium held on Monday, December 5 in Toronto drew over 400 people this year from across the province and beyond to hear a variety of interesting talks on the theme of Innovating Towards Transformative Cancer Care.

    Read More View all notices

Featured Patient Story

Bouncing back from radiation treatment to treat brain tumour

When Valeriya Zolotorgova was 10, her mother began to notice significant changes in the young girl’s hearing and vision. Following visits to doctors, Valeriya was eventually diagnosed with a brain tumour, medulloblastoma, the most common childhood malignant brain tumour with a 30 to 40 per cent mortality rate.

Read the full story
More patient stories

Watch our videos about TFRI-funded research on glioblastoma.

Our Mission & Vision

Terry's vision unites us and inspires our research excellence, innovation and creativity. The Terry Fox Research Institute is a collaboratively oriented, pan-Canadian organization focused on improving cancer research outcomes for the benefit of cancer patients everywhere. We invest in and manage translational research projects across Canada and function as the research arm of The Terry Fox Foundation, managing and overseeing its discovery and training portfolios. We want to ensure that today’s best science becomes tomorrow’s affordable medicine.


Back to Top